Literature DB >> 23276464

Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma.

Zora Baretta1, Rodrigo Santa Cruz Guindalini, Galina Khramtsova, Olufunmilayo I Olopade.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23276464      PMCID： PMC4816219          DOI： 10.1016/j.clbc.2012.11.007

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  17 in total

Review 1.  Mucins in cancer: protection and control of the cell surface.

Authors:  Michael A Hollingsworth; Benjamin J Swanson
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

2.  Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.

Authors:  Wolfgang J Köstler; Barbara Schwab; Christian F Singer; Rainer Neumann; Ernst Rücklinger; Thomas Brodowicz; Sandra Tomek; Monika Niedermayr; Michael Hejna; Günther G Steger; Michael Krainer; Christoph Wiltschke; Christoph C Zielinski
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

3.  Mucinous breast carcinoma: a large contemporary series.

Authors:  Christina R Barkley; Jennifer A Ligibel; Julia S Wong; Stuart Lipsitz; Barbara L Smith; Mehra Golshan
Journal:  Am J Surg       Date:  2008-10       Impact factor: 2.565

4.  Should liver metastases of breast cancer be biopsied to improve treatment choice?

Authors:  G Curigliano; V Bagnardi; G Viale; L Fumagalli; N Rotmensz; G Aurilio; M Locatelli; G Pruneri; S Giudici; M Bellomi; P Della Vigna; L Monfardini; F Orsi; F Nolè; E Munzone; A Goldhirsch
Journal:  Ann Oncol       Date:  2011-02-22       Impact factor: 32.976

5.  The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.

Authors:  Xiao-Feng Le; Francois-Xavier Claret; Amy Lammayot; Ling Tian; Deepa Deshpande; Ruth LaPushin; Ana M Tari; Robert C Bast
Journal:  J Biol Chem       Date:  2003-04-16       Impact factor: 5.157

6.  The importance of histologic type on breast cancer survival.

Authors:  M E Northridge; G G Rhoads; D Wartenberg; D Koffman
Journal:  J Clin Epidemiol       Date:  1997-03       Impact factor: 6.437

7.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

Authors:  Peter Nagy; Elza Friedländer; Minna Tanner; Anita I Kapanen; Kermit L Carraway; Jorma Isola; Thomas M Jovin
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

Review 8.  Mucinous breast lesions: diagnostic challenges.

Authors:  P H Tan; G M K Tse; B H Bay
Journal:  J Clin Pathol       Date:  2007-09-14       Impact factor: 3.411

Review 9.  Breast carcinoma--rare types: review of the literature.

Authors:  R Yerushalmi; M M Hayes; K A Gelmon
Journal:  Ann Oncol       Date:  2009-07-14       Impact factor: 32.976

10.  A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.

Authors:  Salomone Di Saverio; Juan Gutierrez; Eli Avisar
Journal:  Breast Cancer Res Treat       Date:  2007-11-18       Impact factor: 4.872
View more
  7 in total

1.  Development and verification of a personalized immune prognostic feature in breast cancer.

Authors:  HongLei Wang; Li Wu; HongTao Wang
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-29

Review 2.  Invasive mucinous carcinoma arising in ectopic axillary breast tissue: a case report and literature review.

Authors:  Salvatore M Nardello; Nandani Kulkarni; Allison Aggon; Marcia Boraas; Elin R Sigurdson; Richard J Bleicher
Journal:  Am J Case Rep       Date:  2015-03-14

3.  Her-2 positive mucinous carcinoma breast cancer, case report.

Authors:  Irean Garcia Hernandez; Mauricio Canavati Marcos; Margarita Garza Montemayor; Dulce Lopez Sotomayor; Diana Pineda Ochoa; Gabriela Sofia Gomez Macias
Journal:  Int J Surg Case Rep       Date:  2017-12-26

4.  Biomarker discovery to improve prediction of breast cancer survival: using gene expression profiling, meta-analysis, and tissue validation.

Authors:  Liwei Meng; Yingchun Xu; Chaoyang Xu; Wei Zhang
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

5.  Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.

Authors:  Callie R Merry; Sarah McMahon; Megan E Forrest; Cynthia F Bartels; Alina Saiakhova; Courtney A Bartel; Peter C Scacheri; Cheryl L Thompson; Mark W Jackson; Lyndsay N Harris; Ahmad M Khalil
Journal:  Oncotarget       Date:  2016-08-16

6.  Aggressive behavior of Her-2 positive colloid breast carcinoma: A case report in a metastatic breast cancer.

Authors:  Sumadi Lukman Anwar; Ery Kus Dwianingsih; Widya Surya Avanti; Lina Choridah; Teguh Aryandono
Journal:  Ann Med Surg (Lond)       Date:  2020-03-10

Review 7.  HER2-positive pure mucinous breast carcinoma: A case report and literature review.

Authors:  Xingjuan Zhao; Xuan Yang; Runfang Gao; Liqin Zhai; Lizhu Yang; Keda Yu
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.